Plenary Speaker: David A. DeGoey, PhD

Research Fellow @ AbbVie 

Beyond the Rule of 5 - Title TBA

Plenary Speaker: Jean-Claude Marshall, PhD

Head of Clinical Biomarkers @ Moderna

Biomarker challenges for assay decelopment for COVID19 vaccines and therapeutics - title TBA

Professor Jan Kihlberg,PhD

Organic Chemistry, Uppsala University, Sweden

Molecular Chameleonicity and Cell Permeability of Drugs and PROTACs in the bRo5 Space

MatthiasWittwer,PhD

PDM Project Leader @ Roche

Optimizing Proteolysis - Targeting PROTAC for Oral Drug Delivery: A Drug Metabolism and PK Perspective

Danielle Swaney, PhD

Assistand Adjunct Professor @ UCSF

Discovery of SARS-CoV-2 Host-protein Targets for Antiviral Drug Repurposing

Tao Jiang, PhD

Senior Scientist @ Moderna

Title TBA - COVID19

 Criziel Quinn, MT, MB (ASCP)

Diagnostic Lab Team Leader, The Molecular Infectious Disease lab @ Vanderbilt University Medical Center

COVID19 Testing During Pandemic Times

Sejal Patel, PhD

Associate Principal Scientist @ Merck

Large Molecule Bioanalysis for Oncolytic Therapeutics - BA Assay Lifecycle Management 

 Noah Post, PhD

Assistant Director @ Ionis Pharmaceuticals

Bioanalysis of Therapeutic Oligonucleotides Using LC-MS and ELISA

Edward Price, PhD

Senior Scientist I @ AbbVie

A Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Pre-clinical Models

Fabio Broccatelli, PhD

Senior Scientist @ Genentech

Tissue Binding in Predictive Modeling and Drug Design

Alexander Kozhich, PhD

Director @ Bristol Myers Squibb

Cell Therapy - Title TBA 

Vaishali Dixit, PhD

Director, DMPK/Preclinical Development @ Kymera Therapeutics

"Can We Predict the Vss and Tissue Distribution of Targeted Protein Degraders Using Mechanistic PBPK Models?"

Andrew Melton, PhD

Associate Director @ BioMarin Pharmaceutical

ddPCR work assay development and validation for gene therapies/linkage analysis and multiplexing - Title TBA

Jennifer Zimmer, PhD

Laboratory Director @ Alturas Analytics

Bioanalytical Challenges: Developing a rugged chiral assay for the biomarker 2-hydroxyglutaric acid for use in routine clinical analysis of plasma samples from oncology studies

Julie Seroogy, PhD

Senior Director, Clinical Pharmacokinetics, MyoKardia/BMS

Bioanalytical Approaches to Support Individualized Dosing in Global Clinical Studies 

 Dr. Brahim Achour

Research Associated, Centre for Applied Pharmacokinetics Research (CAPKR), University of Manchaster

Title TBA - Liquid Biopsy

Li Di, PhD

Research Fellow @ Pfizer

What is HLM-HHEP Disconnect Telling Us?

Abbas Bandukwala, MS

Science Policy Analyst, Office of New Drugs/CDER, U.S. Food and Drug Administration

Analytical Considerations for Biomarker Development and Qualification

Kevin Bateman, PhD

Scientific Associate Vice President @ Merck

Lab of the Future 

Diane Ramsden, PhD

Associate Scientific Director Global DMPK @ Takeda

Developing Oligonucleotide Therapeutics, Considerations for DMPK Scientists